Key Points
- Director Mark Alvino sold 15,000 shares on Nov. 13 at an average price of $4.74 for $71,100, reducing his stake by 19.42% to 62,252 shares; the transaction was disclosed in an SEC filing.
- ABEO traded down about 1.8% to $4.45 on Friday on heavier-than-average volume (2.64M vs. 1.16M average), with a market cap near $241 million and a 52-week range of $3.93–$7.54.
- Abeona beat quarterly EPS estimates (reported ($0.10) vs. consensus ($0.27)), and despite mixed analyst moves the consensus rating is a "Moderate Buy" with a $20 consensus target price.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 15,000 shares of the company's stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $4.74, for a total transaction of $71,100.00. Following the completion of the sale, the director directly owned 62,252 shares in the company, valued at $295,074.48. This represents a 19.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Abeona Therapeutics Stock Down 1.8%
NASDAQ ABEO traded down $0.08 during trading hours on Friday, reaching $4.45. 2,636,102 shares of the company's stock traded hands, compared to its average volume of 1,155,498. Abeona Therapeutics Inc. has a 52-week low of $3.93 and a 52-week high of $7.54. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65. The firm has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $5.97. The firm has a market cap of $241.15 million, a PE ratio of 6.36 and a beta of 1.45.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.17. Sell-side analysts anticipate that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the company. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings lowered shares of Abeona Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, October 24th. Oppenheimer upped their target price on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research note on Friday, August 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.00.
Check Out Our Latest Stock Analysis on Abeona Therapeutics
Hedge Funds Weigh In On Abeona Therapeutics
Hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in shares of Abeona Therapeutics by 64.1% during the 1st quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company's stock valued at $729,000 after acquiring an additional 59,832 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its position in Abeona Therapeutics by 11.0% during the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after purchasing an additional 7,155 shares during the period. Trexquant Investment LP lifted its position in Abeona Therapeutics by 74.1% during the first quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company's stock valued at $568,000 after purchasing an additional 50,758 shares during the period. Newtyn Management LLC boosted its holdings in Abeona Therapeutics by 26.3% in the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company's stock worth $954,000 after purchasing an additional 66,422 shares during the period. Hedge funds and other institutional investors own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
